Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Hansen Ho"'
Autor:
Li Zhang, Divya Natesan, Lawrence Fong, Emily Chan, David Y Oh, Son Ho, Ivan de Kouchkovsky, Errol J Philip, Francis Wright, Daniel M Kim, Daniel Kwon, Hansen Ho, Sima P Porten, Anthony C Wong, Arpita Desai, Franklin W Huang, Jonathan Chou, Raj S Pruthi, Eric J Small, Terence W Friedlander, Vadim S Koshkin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Immune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to
Externí odkaz:
https://doaj.org/article/daffc1a2d771420089913bf03e6aaad2
Publikováno v:
Journal of Hematology Oncology Pharmacy; Apr2024, Vol. 14 Issue 2, p70-78, 9p
Autor:
Rose Monahan, Fernanda Young, Emely Alfaro, Carlo Legasto, Dorothy Wang, Jessica Zheng, Lulu Tsao, Hansen Ho, Iris Otani
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99710dd32897f914ffa0fbcaa0a57f71
https://doi.org/10.1016/j.jaci.2022.12.124
https://doi.org/10.1016/j.jaci.2022.12.124
Publikováno v:
Journal of Clinical Oncology. 40:322-322
322 Background: Bevacizumab-awwb and bevacizumab are vascular endothelial growth factor (VEGF) inhibitors that are commonly combined with other oncolytic agents for the treatment of various malignancies. Real-world outcomes and financial impact of bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::433d63657e81475d454abfa54c2f1af0
https://doi.org/10.1200/jco.2022.40.28_suppl.322
https://doi.org/10.1200/jco.2022.40.28_suppl.322
Autor:
Vadim S. Koshkin, Sima P. Porten, Anthony C. Wong, David Y. Oh, Lawrence Fong, Arpita Desai, Ivan de Kouchkovsky, Eric J. Small, Francis Wright, Hansen Ho, Daniel Kwon, Errol J. Philip, Raj S. Pruthi, Divya Natesan, Terence W. Friedlander, Son Ho, Li Zhang, Jonathan Chou, Emily Chan, Franklin W. Huang, Daniel M Kim
Publikováno v:
Journal for immunotherapy of cancer, vol 9, iss 5
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
BackgroundImmune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use of tumor genomic profiling in clinical practice may help suggest biomarkers to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6155b5d264e08c0cca1f68c52f39ea2d
https://escholarship.org/uc/item/9846n1dp
https://escholarship.org/uc/item/9846n1dp
Publikováno v:
Journal of Allergy and Clinical Immunology. 149:AB173
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c8ff080e9dbbfc5e8d6d2ef9ed43a1a
https://doi.org/10.1016/j.jaci.2021.12.572
https://doi.org/10.1016/j.jaci.2021.12.572
Autor:
Francis Wright, Terence W. Friedlander, Raj S. Pruthi, Jonathan Chou, Li Zhang, Sima P. Porten, Daniel Myung Kim, Vadim S. Koshkin, Daniel Kwon, Ivan de Kouchkovsky, Son Ho, Hansen Ho, Emily Chan, David Y. Oh, Errol J. Philip, Eric J. Small, Franklin W. Huang, Lawrence Fong, Arpita Desai, Divya Natesan
Publikováno v:
Journal of Clinical Oncology. 39:476-476
476 Background: Reliable predictive markers are lacking in patients (pts) with locally advanced or metastatic urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICI). We sought to determine whether specific genomic alterations coul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0807bfb3304c6bbeb52c767c8ff3c6cd
https://doi.org/10.1200/jco.2021.39.6_suppl.476
https://doi.org/10.1200/jco.2021.39.6_suppl.476
Autor:
Hala T. Borno, Errol J. Philip, Vadim S. Koshkin, Edna Cheung, Terence W. Friedlander, Jonathan Chou, Hansen Ho, Lawrence Fong, Daniel Myung Kim, Sima P. Porten, Francis Wright, Arpita Desai, Rahul Aggarwal, Eric J. Small, Daniel Kwon, Anthony C. Wong, Son Ho, David Y. Oh, Emily Chan
Publikováno v:
Journal of Clinical Oncology. 38:502-502
502 Background: ICIs are effective agents in metastatic urothelial carcinoma in both platinum-refractory and frontline settings. Responses in patients (pts) with non-urothelial histological variants are not well defined. Methods: We undertook a retro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8748da88a5e2cb26cc7e73d0cbc0ac7
https://doi.org/10.1200/jco.2020.38.6_suppl.502
https://doi.org/10.1200/jco.2020.38.6_suppl.502
Publikováno v:
Journal of Oncology Pharmacy Practice. 22:261-264
Background The addition of pertuzumab to trastuzumab and taxane therapy was shown to be an effective first-line treatment for patients with HER2-positive metastatic breast cancer. Objective Describe the progression-free survival of pertuzumab, trastu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7581d98076b7df329a3c10a6bb50c750
https://doi.org/10.1177/1078155215578494
https://doi.org/10.1177/1078155215578494
Autor:
Courtney Yuen, Hansen Ho
Publikováno v:
Journal of Oncology Pharmacy Practice. 16:137-138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffba4f5022f950b13a31c4e3bc28aabb
https://doi.org/10.1177/1078155209346072
https://doi.org/10.1177/1078155209346072